Analysts See $-0.28 EPS for Intec Pharma Ltd. (NTEC)

May 17, 2018 - By Hannah Black

Intec Pharma Ltd. (NASDAQ:NTEC) Logo

Analysts expect Intec Pharma Ltd. (NASDAQ:NTEC) to report $-0.28 EPS on June, 8.After having $-0.39 EPS previously, Intec Pharma Ltd.’s analysts see -28.21 % EPS growth. The stock decreased 3.09% or $0.15 during the last trading session, reaching $4.7. About 210,925 shares traded. Intec Pharma Ltd. (NASDAQ:NTEC) has risen 25.00% since May 18, 2017 and is uptrending. It has outperformed by 13.45% the S&P500.

Intec Pharma Ltd., a clinical stage biopharmaceutical company, focuses on developing drugs based on its proprietary Accordion Pill platform technology in Israel. The company has market cap of $159.15 million. The Company’s Accordion Pill is an oral drug delivery system that is designed to enhance the efficacy and safety of existing drugs and drugs in development by utilizing a gastric retention and specific release mechanism. It currently has negative earnings. The company's lead product candidate is Accordion Pill Carbidopa/Levodopa , which is in a Phase III clinical trial for the treatment of Parkinson's disease symptoms in advanced Parkinson's disease patients.

Another recent and important Intec Pharma Ltd. (NASDAQ:NTEC) news was published by Prnewswire.com which published an article titled: “Intec Pharma Reports First Quarter 2018 Financial Results and Corporate Update” on May 15, 2018.

Intec Pharma Ltd. (NASDAQ:NTEC) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.